Icon

VITRAKVI (nda210861)- (EQ 25MG BASE,EQ 100MG BASE)

LAROTRECTINIB SULFATE BAYER HLTHCARE
EQ 25MG BASE,EQ 100MG BASE
No No
2036-Aug-15 2023-Nov-26
None None
None No
VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:  have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,  are metastatic or where surgical resection is likely to result in severe morbidity, and  have no satisfactory alternative treatments or that have progressed following treatment.
0 0 0
Total Other Developers 4
Drugs with Suitability No
EQ 25MG BASE ** ** - - -
EQ 100MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.